Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology (Q36632771)

15 August 2017

1 reference

title

Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology (English)

1 reference

15 August 2017

0 references

John O'Brien

2

0 references

Alistair Burns

object named as

Alistair Burns

1

0 references

Martin Knapp

10

object named as

Martin Knapp

1 reference

15 August 2017

20

Craig Ritchie

1 reference

15 August 2017

5

Clive Ballard

1 reference

15 August 2017

14

Roy Jones

1 reference

15 August 2017

12

Steve Iliffe

1 reference

British Association for Psychopharmacology

15 August 2017

25

object named as

British Association for Psychopharmacology

1 reference

15 August 2017

BAP Dementia Consensus group

3

1 reference

15 August 2017

Sophie Auriacombe

4

1 reference

15 August 2017

Karl Broich

6

1 reference

15 August 2017

Roger Bullock

7

1 reference

15 August 2017

Howard Feldman

8

1 reference

15 August 2017

Gary Ford

9

1 reference

15 August 2017

Andrew McCaddon

11

1 reference

15 August 2017

Claudia Jacova

13

1 reference

15 August 2017

Sean Lennon

15

1 reference

15 August 2017

Ian McKeith

16

1 reference

15 August 2017

Jean-Marc Orgogozo

17

1 reference

15 August 2017

Nitin Purandare

18

1 reference

15 August 2017

Mervyn Richardson

19

1 reference

15 August 2017

Alan Thomas

21

1 reference

15 August 2017

James Warner

22

1 reference

15 August 2017

Gordon Wilcock

23

1 reference

15 August 2017

David Wilkinson

24

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

Journal of Psychopharmacology

15 August 2017

1 reference

15 August 2017

20

1 reference

15 August 2017

6

1 reference

15 August 2017

732-755

1 reference

Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia

15 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

The MRI pattern of frontal and temporal brain atrophy in fronto-temporal dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Diagnosing dementia: perspectives of primary care physicians.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

L-dopa responsiveness in dementia with Lewy bodies, Parkinson disease with and without dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Switching cholinesterase inhibitor therapy in Alzheimer's disease--donepezil to rivastigmine, is it worth it?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Sensory stimulation in dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Differential effects of lipid-lowering agents on human cholinesterases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Diagnosis and management of dementia in primary care at an early stage: the need for a new concept and an adapted procedure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Switching from donepezil or rivastigmine to galantamine in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Treatment of vascular dementia--evidence from clinical trials with cholinesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

The effect of different diagnostic criteria on the prevalence of dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Cognition, function, and caregiving time patterns in patients with mild-to-moderate Alzheimer disease: a 12-month analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Linear width of the medial temporal lobe can discriminate Alzheimer's disease from normal aging: the Sunnybrook dementia study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Long-Term Cholinesterase Inhibitor Therapy for Alzheimer's Disease: Practical Considerations for the Primary Care Physician

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

The potential role of non-steroidal anti-inflammatory drugs in treating Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Untangling vascular dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Statins and the risk of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

The prevalence of dementia: a quantitative integration of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Dementia with Lewy bodies: response of delirium-like features to donepezil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Statin therapy in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Combination therapy of donepezil and vitamin E in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Midlife blood pressure and dementia: the Honolulu-Asia aging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Hormone replacement therapy and cognition: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Identification of cognitive impairment in the elderly: homocysteine is an early marker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association for Psychopharmacology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Total serum homocysteine in senile dementia of Alzheimer type

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Homocysteine and cognitive decline in healthy elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Neuroleptic sensitivity in patients with senile dementia of Lewy body type

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Folic acid with or without vitamin B12 for cognition and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Guidelines for treating depressive illness with antidepressants: A statement from the British Association for Psychopharmacology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Postmenopausal hormone replacement therapy: scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Vitamin E and donepezil for the treatment of mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Statin Use and the Risk of Incident Dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Potential treatment effects of donepezil not detected in Alzheimer's disease clinical trials: a physician survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Switching From Donepezil to Rivastigmine Is Well Tolerated: Results of an Open-Label Safety and Tolerability Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

21 January 2018

Memantine for dementia

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

A study of statin use in the prevention of cognitive impairment of vascular origin in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Fatal aspiration pneumonia during transition from donepezil to rivastigmine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Midlife cardiovascular risk factors and risk of dementia in late life

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Donepezil in vascular dementia: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Switching from donepezil to galantamine: a double-blind study of two wash-out periods

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Dementia: issues in early recognition and intervention in primary care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Caring for patients with dementia: The GP perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Shortcomings in the diagnosis and management of dementia in primary care: Towards an educational strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

Editorial: The hazards of early recognition of dementia: a risk assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106068299

21 January 2018

Identifiers

DOI

10.1177/0269881106068299

1 reference

15 August 2017

1 reference